Cerus. has filed a patent for detecting antibodies in biological samples, especially in patients treated with pathogen-inactivating compounds. The patent includes compositions, methods, kits, and systems for this purpose. GlobalData’s report on Cerus gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Cerus Corp - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Cerus, Automatic disinfection robots was a key innovation area identified from patents. Cerus's grant share as of January 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.

Detecting antibodies in biological samples against pathogen-inactivating compound treated rbcs

Source: United States Patent and Trademark Office (USPTO). Credit: Cerus Corp

The patent application (Publication Number: US20230408490A1) describes a method for testing a sample for the presence of antibodies reactive to pathogen-inactivated red blood cells. The method involves providing a sample from a potential recipient, contacting the sample with red blood cells bound with a specific moiety, and comparing the binding between antibodies in the sample and the surface-bound moiety with a reference to determine the presence of reactive antibodies. The surface-bound moiety can be a non-frangible analog of S-303 or a salt thereof, present at a specific loading level per red blood cell.

Furthermore, the patent application also discloses a method for providing a red blood cell transfusion to a patient treated with pathogen-inactivating compounds. This method includes testing a sample from the patient for the presence of antibodies as described earlier, determining the binding levels compared to a reference, and providing the transfusion based on the binding results. The surface-bound moiety in this method can also be a non-frangible analog of S-303 or a salt thereof, with specific chemical properties outlined in the claims. These methods aim to ensure the safety and efficacy of red blood cell transfusions by detecting antibodies reactive to pathogen-inactivated red blood cells before administering the transfusion to the patient.

To know more about GlobalData’s detailed insights on Cerus, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies